USAS Building System Listed on the Hong Kong Stock Exchange: A Top-Three Industrial Prefabricated Steel Structure Solution Provider Enters a New Phase in the Capital Markets 
DEFSEC Technologies Inc. Announces Full Year Fiscal 2025 Results and Outlook for Fiscal 2026 
The FUTR Corporation Announces Enterprise Agreement with Direct Wholesale Rates to Expand AI-Powered Mortgage, Payments, and Home Concierge Services in the U.S. 
Pineapple Financial Appoints Anthony Georgiades to Board of Directors and Special Advisory Committee 
Gatekeeper Reports $31.8M Revenue in Fiscal 2025 Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
— NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a…
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
On track to report initial VOR33 clinical data in the first half of 2022 Announced…
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase…
Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results
Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in…
NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates
Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003 Advancing two lead product candidates…
Recro Reports Second Quarter 2021 Financial Results
Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2…
Tricida Announces Second Quarter 2021 Financial Results
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE…
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
– SAD cohorts up to 640 mg and MAD cohorts up to 320 mg completed…
VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (NASDAQ: VTGN),…
Organogenesis Holdings Inc. Reports Second Quarter and First Half 2021 Financial Results
CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
Phase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive…
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
Cara Therapeutics Reports Second Quarter 2021 Financial Results
– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by…
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
Received approval for EMPAVELI™ (pegcetacoplan) – the first targeted C3 therapy – from U.S. Food and…
Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical…
FibroGen Reports Second Quarter 2021 Financial Results
• Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. •…
NexImmune to Explore the Use of AIM™ Direct Injection Technology in Type 1 Diabetes
GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank
CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Adaptimmune Reports Second Quarter Financial Results and Business Update
– SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma…
Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a…